Born 1967. Chairman of the board of directors since 2017.
Education: MBA from Stockholm School of Economics.
Experience: Thomas Eklund has extensive experience in the pharmaceutical and medtech industry as well as the financial sector. He has held different executive positions, including CEO and Head of Europe at Investor Growth Capital AB. His previous positions include Investment Director at Alfred Berg ABN AMRO Capital Investment AB and Vice President at Handelsbanken Markets.
Other current assignments: Chairman of the board of directors of Itrim Holding AB, Moberg Pharma AB (publ) and Sedana Medical AB (publ). Member of the board of directors of Biotage AB, Boule Diagnostics AB, Eklund konsulting AB, Excillum Aktiebolag, Memira Holding AB, Neoventa Medical AB, Rodebjer Form AB, SciBase AB, SciBase Holding AB (publ), SciBase Intressenter AB, Surgical Science Sweden AB, Swedencare AB (publ) and TEDCAP AB.
Previous assignment (last five years): Chairman of the board of directors of BoMill AB, Swevet AB, Swevet Holding AB and Swevet-Piab Aktiebolag. Chairman of the board of directors and member of the board of directors of GHP Specialty Care AB (publ). Member of the board of directors of Annexin Pharmaceuticals AB, Bariatric and Diabetes Center Ajman AB, Circassia AB, GHP International AB, GHP Specialisttandläkarna AB, Neoventa Holding Aktiebolag, Observe Medical International AB, PocketMobile Communications Aktiebolag and Vårdapoteket i Norden AB. Deputy member of the board of directors of Newron Sweden AB and Tobii AB.
Born 1958. Board member since 2014.
Education: Master of Science in Chemistry from the University of Oslo, Norway.
Experience: Hilde Furberg has more than 30 years of experience in sales, marketing and business management in the pharmaceutical industry. Hilde Furberg has experience from several therapeutic areas and specialized knowledge on kidney related diseases and orphan diseases. She is currently Head of Rare Disease Europe at Sanofi Genzyme, which she joined in 2002 as the Nordic General Manager. Prior to Genzyme, Hilde Furberg spent 15 years at Baxter in various business roles. Hilde Furberg has important competence in the sales, marketing, strategizing, launching and commercial implementation of projects regarding pharmaceutical products.
Other current assignments: Member of the board of directors of BerGenBio. Head of Rare Disease Europe of Sanofi Genzyme. Partner of J&J Future Invest.
Previous assignment (last five years): Member of the board of directors of Algeta ASA, Clavis ASA, Genzyme AB, Genzyme AS and Pronova ASA.
Born 1956. Board member since 2009.
Education: PhD in Genetics from the University of Umeå.
Experience: Lennart Hansson is an Investment Director at Industrifonden, an independent foundation founded by the Swedish state in 1979 and which operates on a commercial basis without outside capital. Lennart Hansson has broad experience in the life science sector and has worked in leading and executive positions at KabiGen AB, Symbicom AB, AstraZeneca, Arexis AB, Biovitrum AB and Karolinska Development AB.
Other current assignments: Chairman of the board of directors of Sixera Pharma AB and Ignitus AB. Member of the board of directors of Athera Biotechnologies AB (publ), Cinclus AG and InDex Pharmaceuticals Holding AB (publ). Deputy member of the board of directors of Airsonett Holding AB and Smartfish AS. Employed by Stiftelsen Industrifonden.
Previous assignment (last five years): Member of the board of directors of CMC Contrast Aktiebolag, InDex Diagnostics AB, InDex Pharmaceuticals AB, Malmö Industrifinans AB, Medtentia International OY, Uminova Invest AB and OxThera AB.
Born 1965. Board member since 2014.
Education: Bachelor of Business Administration from Hofstra University. MBA from IESE Business School.
Experience: Olav Hellebø is CEO of the UK-listed ReNeuron Group plc and the chairman of the board of directors and co-founder of Palma Biotech S.L. in Spain. He is an experienced pharmaceutical executive who has held senior positions in the pharmaceutical industry in both Europe and the US. Previously, Olav Hellebø was CEO of Clavis Pharma ASA and before that he was Senior Vice President of UCB Pharma and President of Immunology Operations. In this position, he built and led the global organization responsible for the successful registration and launch of Cimzia®, UCB’s antibody drug for the treatment of rheumatoid arthritis and Crohn’s disease.
Other current assignments: Chairman of the board of directors of Barcelona Bioscience. Member of the board of directors and CEO of ReNeuron.
Previous assignment (last five years): CEO of Clavis Pharma.
Born 1953. Board member since 2004.
Education: Master of Pharmacy from Uppsala University.
Experience: Bengt Julander is a pharmacist and has worked in the pharmaceutical industry since 1978. He is the CEO of Linc AB, which invests in life sciences, including the Company. Since 1990, Bengt Julander has been primarily active as an investor in, and a board member of, pharmaceutical development companies. He has experience of developing and commercializing pharmaceutical products.
Other current assignments: Chairman of the board of directors of Knil AB. Member of the board of directors of Linc AB, Medivir Aktiebolag, Stille AB, Nefecon AB, Swevet AB, ProEquo AB, Sedana Medical AB (publ), Busulipo AB, nWise AB, Swevet Holding AB, Pharmalink Nordic AB and Cronhamn Invest AB. Deputy member of the board of directors of Kv Eldstaden I Bromma AB, Algarvefastigheter AB, Eriksbergskliniken Gam AB, Linc Global AB, Linc International AB, Korkyl Holding AB, Eriksbergskliniken AB and Linc Trade AB.
Previous assignment (last five years): Chairman of the board of directors of MedCap AB (publ). Member of the board of directors of Abilia Sverige Holding AB, Anmedic Aktiebolag, Anmedic Holding AB, Bringwell AB (publ), Handitek AB, Intersurgical AB, LK Distribution AB, Swevet-Piab Aktiebolag and Unimedic Aktiebolag. Member of the board of directors, CEO and liquidator of Linc Aktiebolag. Deputy member of the board of directors of Bromma Advokat AB, Cardiolex Medical AB, Dunmedic AB, Gewab Aktiebolag, Korkyl AB and Sandvikens Företagspark Förvaltning AB.
Born 1967. Board member since 2013.
Education: Master of Science in Economics and Business Administration from Bodø Graduate School of Business. Advance Program in Corporate Finance at Norwegian School of Economics.
Experience: Ann-Tove Kongsnes has 18 years’ experience of active ownership and investments, development, transactions, divestments and IPO of technology companies. Ann-Tove Kongsnes is an Investment Director at Investinor, Norway’s largest investor in venture and expansion capital and an investor in Calliditas. Before this, she worked 7 years in international marketing, as the Directors of Marketing and Operations. Ann-Tove Kongsnes has years of experience as an investor and a broad experience in board activities.
Other current assignments: Member of the board of directors and deputy chairman of the board of Vitux AS (Ayanda) and poLight AS. Member of the board of directors of Numascale AS and Spinchip Diagnostics AS. Deputy member of the board of directors of Boost AS, Boostcom Group AS, Data-Consult AS, Fondstiftelsen ved St. Olavs Hospital and Orientekspressen AS. Employed by Investinor AS.
Previous assignment (last five years): Member of the board of directors of Nordic Halibut AS, NTNU Technology Transfer, Soundrop AS and Santosolve AS. Deputy member of the board of directors of Bergenbio AS.